Use of antineoplastic agents in patients with cancer who have HIV/AIDS

Lancet Oncol. 2011 Sep;12(9):905-12. doi: 10.1016/S1470-2045(11)70056-0. Epub 2011 May 12.

Abstract

Highly active antiretroviral therapy (HAART) has substantially reduced morbidity and mortality of AIDS-related complications in patients with HIV; however, the prevalence of AIDS-defining cancers and non-AIDS-defining cancers has increased. In this Review we discuss the management of HAART pharmacotherapy in relation to cytotoxic chemotherapy or targeted antineoplastic agents. We will review potential pharmacological interactions between antiretroviral and antineoplastic therapies and consider how to combine antiretroviral and antineoplastic agents in patients with HIV who are receiving HAART therapy.

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Acquired Immunodeficiency Syndrome / complications
  • Acquired Immunodeficiency Syndrome / drug therapy*
  • Anti-HIV Agents / adverse effects
  • Anti-HIV Agents / pharmacokinetics
  • Anti-HIV Agents / therapeutic use*
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / pharmacokinetics
  • Antineoplastic Agents / therapeutic use*
  • Antiretroviral Therapy, Highly Active
  • Drug Interactions
  • HIV Infections / complications
  • HIV Infections / drug therapy*
  • Humans
  • Neoplasms / complications
  • Neoplasms / drug therapy*
  • Risk Assessment
  • Risk Factors

Substances

  • Anti-HIV Agents
  • Antineoplastic Agents